High-CSD melanomas have a threefold higher tumor mutation burden than low-CSD melanomas [21], and a higher mutation burden is associated with enhanced sensitivity to ICIs, including anti-PD-1 [22]. The gene discussed is PDCD1; the disease is neoplasm.